These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 23748404)

  • 1. The New Zealand Centre for Adverse Reactions Monitoring: a source of practice-based evidence.
    Savage R
    J Prim Health Care; 2013 Jun; 5(2):170-3. PubMed ID: 23748404
    [No Abstract]   [Full Text] [Related]  

  • 2. Statin-associated rhabdomyolysis.
    Ardati A; Stolley P; Knapp DE; Wolfe SM; Lurie P
    Pharmacoepidemiol Drug Saf; 2005 Apr; 14(4):287. PubMed ID: 15782398
    [No Abstract]   [Full Text] [Related]  

  • 3. Statin safety.
    Foxton J
    Nurs Stand; 2001 Sep 19-25; 16(1):20. PubMed ID: 11977679
    [No Abstract]   [Full Text] [Related]  

  • 4. The withdrawal of Baycol (cerivastatin).
    Griffin JP
    Adverse Drug React Toxicol Rev; 2001 Dec; 20(4):177-80. PubMed ID: 11770168
    [No Abstract]   [Full Text] [Related]  

  • 5. Statins, cardiovascular disease, and drug safety.
    Gotto AM
    Am J Cardiol; 2006 Apr; 97(8A):3C-5C. PubMed ID: 16581326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy.
    Chang JT; Staffa JA; Parks M; Green L
    Pharmacoepidemiol Drug Saf; 2004 Jul; 13(7):417-26. PubMed ID: 15269925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerivastatin and the dissemination of adverse event information.
    Weaver SJ; Doering PL
    Ann Pharmacother; 2002 Jun; 36(6):1099-103. PubMed ID: 12058704
    [No Abstract]   [Full Text] [Related]  

  • 8. [Interactions between statins and macrolide antibiotics].
    Molden E; Andersson KS; Jacobsen D
    Tidsskr Nor Laegeforen; 2007 Jun; 127(12):1660-1. PubMed ID: 17571108
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacovigilance in New Zealand: the role of the New Zealand Pharmacovigilance Centre in facilitating safer medicines use.
    Kunac DL; Harrison-Woolrych M; Tatley MV
    N Z Med J; 2008 Oct; 121(1283):76-89. PubMed ID: 18841188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting errors in the ICU: use of a national database.
    Kleinpell R; Thompson D; Kelso L; Pronovost PJ
    Crit Care Nurs Clin North Am; 2006 Dec; 18(4):509-14. PubMed ID: 17118305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Muscle toxicity with statins.
    Hedenmalm K; Alvan G; Ohagen P; Dahl ML
    Pharmacoepidemiol Drug Saf; 2010 Mar; 19(3):223-31. PubMed ID: 20014178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HMG-CoA-reductase inhibitors and neuropathy: reports to the Netherlands Pharmacovigilance Centre.
    de Langen JJ; van Puijenbroek EP
    Neth J Med; 2006 Oct; 64(9):334-8. PubMed ID: 17057271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin.
    Jones PH; Davidson MH
    Am J Cardiol; 2005 Jan; 95(1):120-2. PubMed ID: 15619408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimating the extent of reporting to FDA: a case study of statin-associated rhabdomyolysis.
    McAdams M; Staffa J; Dal Pan G
    Pharmacoepidemiol Drug Saf; 2008 Mar; 17(3):229-39. PubMed ID: 18175291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. About rhabdomyolysis.
    Harv Heart Lett; 2012 Oct; 23(2):5. PubMed ID: 23437466
    [No Abstract]   [Full Text] [Related]  

  • 16. [Statins--the pattern of adverse effects with empahsis on mental reactions. Data from a national and an international database].
    Buajordet I; Madsen S; Olsen H
    Tidsskr Nor Laegeforen; 1997 Sep; 117(22):3210-3. PubMed ID: 9411859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of aggressive statin therapy.
    Med Lett Drugs Ther; 2004 Nov; 46(1196):93-5. PubMed ID: 15557874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are statins safe?
    Zarowitz BJ
    Geriatr Nurs; 2007; 28(4):212-7. PubMed ID: 17711785
    [No Abstract]   [Full Text] [Related]  

  • 19. [Official systems of pharmacovigilance in France and in Spain. Comparison of spontaneous reporting in two regional centers: Pays Basque and Bordeaux].
    Aguirre C; Haramburu F
    Therapie; 1995; 50(6):563-9. PubMed ID: 8745957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statin safety: an appraisal from the adverse event reporting system.
    Davidson MH; Clark JA; Glass LM; Kanumalla A
    Am J Cardiol; 2006 Apr; 97(8A):32C-43C. PubMed ID: 16581327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.